New Generation Of Cancer Treatments To Be Highlighted At Public Lecture, University Of Leicester

February 13, 2009 at 2:00 pm Leave a comment


Cancer incidences are set to rise to a global annual total of 15 million by 2020, an expert is set to warn at a University of Leicester lecture. Professor Herbie Newell, Professor of Cancer Therapeutics at Newcastle University, will deliver the Redfearn Memorial Lecture on 25 March, 2009. His lecture, Challenges in the Development of Targeted Cancer Therapies, takes place at 4pm in the Henry Wellcome Building, University of Leicester. It is open to the public and free.




Professor Newell said: “Cancer is now the major cause of death from disease in most developed countries, with the annual global cancer incidence estimated to rise to 15 million by 2020. Where causes can be identified, such as cigarette smoking in lung cancer or HPV in cervical cancer, effective prevention strategies have been developed; however, the causes of the majority of cancers remain unknown and hence treatments are required.




“Conventional treatments such as surgery, radiotherapy and cytotoxic chemotherapy are of benefit in many cancer types; however, these treatments do not target the underlying molecular lesions that drive cancer and despite their use the majority of patients currently die of their disease.




“Recently, insights into the molecular and cellular biology of cancer have resulted in a new generation of cancer treatments known as targeted therapies. Central to the use of targeted therapies is the development of complementary biomarkers, or tests, to enable the identification of patients who are most likely to benefit and demonstrate that a new drug is working through its intended mechanism.




“Although early results with targeted therapies are encouraging, limitations are already becoming apparent and approaches to optimizing the use of targeted therapies will also be discussed.”




Professor Newell is Professor of Cancer Therapeutics at Newcastle University and on the board of directors of the Northern Institute for Cancer Research. He is a Scientific Board Member of Astex Technology, has consulted for AstraZeneca Pharmaceuticals, OSI Pharmaceuticals, and has research collaborations with Astex Technology, KuDOS Pharmaceuticals, and Pfizer GRD. Prof Newell was honoured as the 2004 Michel Clavel Award Lecturer at the 16th EORTC/NCI/AACR New Drugs Meeting in Geneva.




The Redfearn Memorial lecture series was established in 1970 to commemorate the life and work of Eric Redfearn, Professor of Biochemistry at the University of Leicester, whose outstanding career was tragically cut short by his death in a road accident at the age of 43. Colleagues and friends established a fund to support a series of lectures in his memory and these have been given by distinguished speakers on a wide range of topics in biology.




The lecture will take place at 4.00pm in the Frank and Katherine May Lecture Theatre, Henry Wellcome Building.



University of Leicester, University Road, Leicester, LE1 7RH United Kingdom

http://www.le.ac.uk

[Via http://www.medicalnewstoday.com]

Advertisements

Entry filed under: Uncategorized.

Durability Of Dental Fillings Improves If The Enzyme Activity Of Teeth Is Inhibited Pelvic Lymph Node Dissection (Extended Vs Standard) And Prostate Cancer

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Trackback this post  |  Subscribe to the comments via RSS Feed


Archives

Top Clicks

  • None

Blog Stats

  • 15,583 hits

%d bloggers like this: